The solution that combines
- determination of dose distribution during patient treatment using a beam model, a transmission detector measurement and a fluence reconstruction
- display of the 3D dose distribution in patient anatomy
- comparison of measured with expected dose distributions.
COMPASS leads you into a new era in the IMRT/IGRT pre-treatment and treatment monitoring as well as verification. It provides truly independent analysis of the accuracy of your planned treatment and the dose delivered to the patient.
COMPASS is a solution to increase the precision and safety of the individual patient treatment.
Your guide to next generation monitoring and verification
A (patent pending) method using a high resolution ionization chamber transmission detector and a Linac beam model allows exact fluence determination and comparison with TPS fluence.
Based on the transmission detector measurement, an advanced forward calculation algorithm subsequently reconstructs the 3D dose distribution in patient anatomy.
The 3D dose distribution is then compared with the TPS. A modern set of software tools incl. DVH allows for a side by side analysis of the two data sets either cumulative or per fraction.
COMPASS is developed in cooperation with RaySearch Laboratories AB.
Patent Pending - FDA 510k approved
|
177 K |
